UPMC Operating Room 1500 5Th Ave Suite 7, Mckeesport, PA 15132 (412)6642110 (Phone)
UPMC Mckeesport General Surgery 500 Hospital Way Suite 6, Mckeesport, PA 15132 (412)6723422 (Phone)
Procedures:
Dressing and/or Debridement of Wound, Infection, or Burn (incl. Negative Pressure Wound Therapy) Excision, Shaving, or Destruction of Skin and Subcutaneous Tissue (incl. Mohs Micrographic Surgery), Tissue Transfer Gallbladder Removal, Laparoscopic Inguinal Hernia Repair, Open
Conditions:
Cholecystitis and Gallstones Inguinal Hernia Lipomas
Certifications:
General Surgery, 2010
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School University of Pittsburgh / Main Campus Graduated: 2003
Breast Disorders Cholelethiasis or Cholecystitis Hemorrhoids Inguinal Hernia Abdominal Hernia
Languages:
English
Description:
Dr. Gribar graduated from the University of Pittsburgh School of Medicine in 2003. He works in McKeesport, PA and 1 other location and specializes in General Surgery. Dr. Gribar is affiliated with UPMC East and UPMC Mckeesport.
UPMC Monroeville
600 Oxford Dr, Monroeville, PA 15146
Education:
University of Pittsburgh
Us Patents
Use Of Toll-Like Receptor-9 Agonists, Toll-Like Receptor-4 Antagonists, And/Or Nuclear Oligomerization Domain-2 Agonists For The Treatment Of Prevention Of Toll-Like Receptor-4-Associated Disorders
The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
Use Of Toll-Like Receptor-9 Agonists, Toll-Like Receptor-4 Antagonists, And/Or Nuclear Oligomerization Domain-2 Agonists For The Treatment Or Prevention Of Toll-Like Receptor-4-Associated Disorders
David J. Hackam - Pittsburgh PA, US Ward M. Richardson - Pittsburgh PA, US Steven C. Gribar - Monroeville PA, US Alexander P. Ducruet - Pittsburgh PA, US
The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.